8-K: Owlet Achieves Record Q3 Revenue, Profit, and EBITDA

Owlet, Inc. reported record third-quarter 2025 financial results, driven by strong sales of Dream Sock and Dream Duo products and significant international growth.

Summary

• Record Q3 Revenue of $32.0 million, marking a 44.6% increase from Q3 2024.
• Record Q3 Gross Profit of $16.2 million, with a gross margin of 50.6%.
• Record Q3 Operating Income of $1.2 million, a significant improvement from an operating net loss of $4.8 million in Q3 2024.
• Record Q3 Net Income of $4.1 million, compared to a net loss of $5.6 million in Q3 2024.
• Record Q3 Adjusted EBITDA (non-GAAP) of $1.6 million, improving $1.0 million compared to Q3 2024.
• International expansion demonstrated approximately 171% growth year-over-year.
• The Owlet360 subscription service surpassed 85,000 paying subscribers.
• Successfully completed a warrant exchange and follow-on equity offering in October, strengthening the business.
• Updated full year 2025 financial outlook projects revenue between $103 million and $106 million (32% to 36% growth), gross margins of 48% to 50%, and adjusted EBITDA of $1.25 million to $2 million.

Sentiment

Score: 8

Explanation: The company reported record financial results across key metrics (revenue, gross profit, operating income, net income, adjusted EBITDA) and demonstrated strong growth in strategic areas like international expansion and subscriptions. The successful capital raise further strengthens its position. The only notable negative is a slight dip in gross margin due to tariffs, but overall, the performance and outlook are very positive.

Positives

• Record Q3 Revenue of $32.0 million, a 44.6% increase from Q3 2024, driven by higher sales of Dream Sock and Dream Duo products.
• Record Q3 Gross Profit of $16.2 million, reflecting strong sales performance.
• Record Q3 Operating Income of $1.2 million, a substantial improvement from an operating loss of $4.8 million in Q3 2024.
• Record Q3 Net Income of $4.1 million, reversing a net loss of $5.6 million from Q3 2024.
• Record Q3 Adjusted EBITDA of $1.6 million, an improvement of $1.0 million year-over-year, indicating enhanced operational efficiency.
• International expansion grew approximately 171% year-over-year, supported by a new regulatory clearance in India.
• The Owlet360 subscription service is maintaining exciting momentum, recently surpassing 85,000 paying subscribers.
• Operating expenses decreased to $15.0 million for Q3 2025 from $16.4 million in Q3 2024, primarily due to the absence of impairment charges related to intangible assets and an insurance loss recovery.
• Successful completion of a warrant exchange and follow-on equity offering in October, strengthening the business and positioning for long-term growth opportunities.

Negatives

• Q3 Gross Margin decreased by 150 basis points to 50.6% from 52.2% in Q3 2024, primarily due to tariff impacts.
• The updated full year 2025 gross margin guidance of 48% to 50% includes the impact of new, increased tariff costs.
• Interest expense, net, was $(0.9) million for Q3 2025, compared to $(0.1) million for Q3 2024.
• Common stock warrant liability adjustment resulted in a $(4.3) million expense for Q3 2025.

Risks

• The regulatory pathway for Owlet's products, including submissions to, actions taken by, and decisions and responses from regulators such as the FDA and similar international bodies, as well as the ability to obtain and maintain regulatory approval or certification.
• Competition within the market and the company's ability to profitably grow and manage that growth.
• The ability to enhance future operating and financial results or obtain additional financing to continue as a going concern.
• Risks associated with obtaining additional financing in the future, current loan and debt agreements, compliance with debt covenants, restrictions on capital access, overall debt levels, and the ability to generate sufficient future cash flows to meet debt service obligations.
• The ability to implement strategic initiatives, reduce costs, grow revenues, develop and launch new products, innovate and enhance existing products, meet customer demands, and adapt to changes in consumer preferences and retail trends.
• The ability to acquire, defend, and protect intellectual property and satisfy regulatory requirements concerning privacy and data protection, breaches, and loss, as well as other risks associated with digital platforms and technologies.
• The ability to maintain relationships with customers, manufacturers, and suppliers, and to retain management and key employees.
• The ability to upgrade and maintain information technology systems.
• Changes in applicable laws or regulations in the United States and other jurisdictions.
• The impact of and disruption to business, financial condition, operations, supply chain, and logistics due to economic and other conditions beyond the company's control, such as health epidemics, macro-economic uncertainties, tariffs or trade restrictions, social unrest, hostilities, natural disasters, or other catastrophic events.
• The possibility of being adversely affected by other economic, business, regulatory, competitive, or other factors, such as changes in discretionary consumer spending and consumer preferences.

Future Outlook

Owlet expects full-year 2025 revenue in the range of $103 million to $106 million, representing 32% to 36% year-over-year growth. Gross margins are projected to be between 48% and 50%, factoring in new tariff costs, and adjusted EBITDA is anticipated to be between $1.25 million and $2 million. The company plans to continue international expansion, with a commercial product launch in India expected in early 2026, and further grow its Owlet360 subscription service and healthcare channels, including the internal piloting of Owlet OnCall telehealth opportunity.

Management Comments

• "Q3 was another outstanding quarter, we believe the best in Owlet history." Jonathan Harris, President and CEO.
• "Owlet set quarterly records for revenue, gross profit, operating income, and adjusted EBITDA, reflecting the momentum of the business as we leverage the first and only FDA-cleared baby monitor currently on the market and the differentiated Dream product platform to expand our market leadership." Jonathan Harris, President and CEO.
• "Looking ahead, we are just beginning to layer in additional growth drivers to the core business that we believe will propel the long-term opportunity for Owlet." Jonathan Harris, President and CEO.
• "International expansion remains strong with approximately 171% growth year-over-year with a new regulatory clearance in India supporting commercial product launch expected in early 2026." Jonathan Harris, President and CEO.
• "Owlet360 subscription is maintaining exciting momentum, recently surpassing 85,000 paying subscribers, with subscriptions rolling out to our first international markets in the coming weeks." Jonathan Harris, President and CEO.
• "Finally, we continue to make progress unlocking healthcare channels, and have begun the internal piloting phase of Owlets telehealth opportunity, Owlet OnCall." Jonathan Harris, President and CEO.
• "In October, we also successfully completed a warrant exchange and follow-on equity offering, strengthening the business and positioning us to pursue long-term growth opportunities." Jonathan Harris, President and CEO.
• "The future is bright for Owlet as we execute on our strategic growth initiatives, maintain strong financial discipline, and continue to drive our transition to a comprehensive pediatric health platform led by our data and digital services." Jonathan Harris, President and CEO.

Industry Context

Owlet operates in the rapidly evolving digital health and infant monitoring market. Its position as the "first and only FDA-cleared baby monitor currently on the market" provides a significant competitive advantage, differentiating it from other consumer-grade monitors. The focus on international expansion, subscription services (Owlet360), and telehealth (Owlet OnCall) aligns with broader industry trends towards recurring revenue models, global market penetration, and integrated digital healthcare solutions. The growth in these areas suggests the company is effectively capitalizing on market demand for advanced pediatric health technology.

Comparison to Industry Standards

• Owlet's claim of having the "first and only FDA-cleared baby monitor currently on the market" positions it uniquely against competitors who may offer similar products but lack the same regulatory clearance, which is a significant barrier to entry and a trust factor for parents.
• The 44.6% year-over-year revenue growth in Q3 2025 is robust, especially when compared to typical growth rates in established consumer electronics or medical device sectors, indicating strong market adoption for its Dream Sock and Dream Duo products.
• The 171% year-over-year international growth suggests successful market penetration strategies in new territories, potentially outpacing global expansion efforts of some competitors in the fragmented infant tech market.
• The achievement of 85,000+ paying subscribers for Owlet360 demonstrates successful adoption of a recurring revenue model, a trend seen across many tech industries, and indicates strong customer loyalty and perceived value for its digital services.
• The transition to profitability (positive operating income and net income) and positive Adjusted EBITDA in Q3 2025 is a key milestone, often a challenge for growth-stage companies in the health tech space, and suggests improved operational efficiency compared to many peers still in heavy investment phases.

Stakeholder Impact

• Shareholders: Positive impact due to record financial performance, improved profitability, and successful capital raise strengthening the balance sheet. Potential for future growth from strategic initiatives.
• Customers: Benefit from continued product innovation (Dream Sock, Dream Duo), expansion of subscription services (Owlet360), and future telehealth options (Owlet OnCall), enhancing the value proposition of Owlet's pediatric health platform.
• Employees: Positive outlook due to business growth and expansion, potentially leading to increased opportunities. Higher compensation expense including accrued bonuses was noted.
• Creditors: Improved financial health and successful capital raise reduce credit risk.

Next Steps

• Commercial product launch in India expected in early 2026.
• Rollout of Owlet360 subscriptions to first international markets in the coming weeks.
• Continue making progress unlocking healthcare channels.
• Continue internal piloting phase of Owlet OnCall telehealth opportunity.
• Execute on strategic growth initiatives.
• Maintain strong financial discipline.
• Drive transition to a comprehensive pediatric health platform led by data and digital services.

Key Dates

Recommendation

The company delivered record financial results across key metrics, including revenue, gross profit, operating income, and net income, demonstrating a significant turnaround to profitability. Strong growth in international markets (171% year-over-year) and subscription services (over 85,000 subscribers) indicates robust market traction and successful execution of strategic initiatives. The successful warrant exchange and follow-on equity offering in October further strengthened the balance sheet, providing capital for future growth. While gross margins were impacted by tariffs, the overall positive momentum, FDA-cleared product differentiation, and clear growth drivers (India launch, telehealth piloting) position Owlet for continued strong performance.

Keywords

Owlet, OWLT, Financial Results, Q3 2025, Earnings, Infant Monitoring, Smart Baby Monitor, FDA-cleared, Dream Sock, Dream Duo, Subscription Service, Owlet360, Telehealth, Owlet OnCall, International Expansion, Warrant Exchange, Equity Offering, Pediatric Health Platform, Revenue Growth, Profitability, Adjusted EBITDA, Tariffs